Loading...
XASX
OCC
Market cap195mUSD
Jul 08, Last price  
1.23AUD
1D
-6.11%
1Q
-1.60%
Jan 2017
223.68%
IPO
232.43%
Name

Orthocell Ltd

Chart & Performance

D1W1MN
P/E
P/S
56.31
EPS
Div Yield, %
Shrs. gr., 5y
11.28%
Rev. gr., 5y
41.24%
Revenues
5m
+25.27%
524,281691,405790,430666,499529,818619,179945,657719,5231,017,9621,531,7184,243,0695,315,375
Net income
-7m
L+14.93%
-1,323,330-2,182,185-3,742,715-3,784,864-4,177,416-5,757,114-5,852,214-6,151,029-9,037,025-9,106,585-6,248,181-7,180,959
CFO
-7m
L
-290,572-1,753,026-2,767,613-3,321,118-3,555,380-4,644,252-4,180,466-5,256,871-4,633,330-6,261,45614,592,580-6,505,126
Earnings
Aug 28, 2025

Profile

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
IPO date
Aug 12, 2014
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
5,315
25.27%
4,243
177.01%
Cost of revenue
16,996
14,740
Unusual Expense (Income)
NOPBT
(11,681)
(10,497)
NOPBT Margin
Operating Taxes
(3,051)
(3,162)
Tax Rate
NOPAT
(8,630)
(7,334)
Net income
(7,181)
14.93%
(6,248)
-31.39%
Dividends
Dividend yield
Proceeds from repurchase of equity
(123)
BB yield
0.17%
Debt
Debt current
149
181
Long-term debt
1,230
763
Deferred revenue
16,071
18,375
Other long-term liabilities
165
169
Net debt
(19,235)
(23,874)
Cash flow
Cash from operating activities
(6,505)
14,593
CAPEX
(927)
(632)
Cash from investing activities
(942)
(632)
Cash from financing activities
3,244
(165)
FCF
(9,585)
10,006
Balance
Cash
20,614
24,818
Long term investments
Excess cash
20,349
24,606
Stockholders' equity
4,533
6,149
Invested Capital
16,926
19,107
ROIC
ROCE
EV
Common stock shares outstanding
202,008
197,213
Price
0.36
1.43%
0.35
-13.58%
Market cap
71,713
3.89%
69,025
-12.45%
EV
52,478
45,151
EBITDA
(11,164)
(9,943)
EV/EBITDA
Interest
61
31
Interest/NOPBT